← Leaderboards
Jinsong Ni
Cloudbreak Therapeutics, Llc
$2,259,579
Attributed
$2,259,579
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2018–19$2M$1.5M$1M$500K$0
'18
'19
Funding mix
By agency
NIH$2,259,579 · 1
By mechanism
R44$2,259,579 · 1
Top collaborators
No co-investigators on record.
Most similar at Cloudbreak Therapeutics, Llc
Same institution · by research overlap
- Rong Yang$1,377,616
Others in their field
Other Emerging Leaders on “Area”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Leonard Freedman · Leidos Biomedical Research, Inc.$164,467,481
Research focus
AreaAstigmatismBlood VesselsCapsuleClinical TrialsClinical Trials Cooperative GroupConduct Clinical TrialsConjunctivaConjunctival PterygiumControlled StudyCorneaDoseDrug KineticsExcisionEye DiseasesEyedropsFda ApprovedFibroblast Growth FactorFollow-UpFundingGrowthGrowth FactorHyperemiaAffect
Grant awards (4)
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$809,052
R44 · FY2019 · EY · contact PI
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$739,062
R44 · FY2019 · EY · contact PI
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$384,505
R44 · FY2018 · EY · contact PI
A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients$326,960
R44 · FY2018 · EY · contact PI